Cargando…

Safety and efficacy of abciximab as an adjunct to percutaneous coronary intervention

Abciximab is a widely studied glycoprotein IIb/IIIa inhibitor, specifically in the setting of patients undergoing percutaneous coronary intervention (PCI). The populations studied have included patients with non-ST-segment acute coronary syndromes, ST-segment elevation myocardial infarction, and ele...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vergara-Jimenez, Jennifer, Tricoci, Pierluigi
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2835553/ https://www.ncbi.nlm.nih.gov/pubmed/20234778

Ejemplares similares

Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis
por: Wu, Yihua, et al.
Publicado: (2011)

Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab
por: Moon, Su-Jin, et al.
Publicado: (2008)

Abciximab: a reappraisal of its use in coronary care
por: Valgimigli, Marco, et al.
Publicado: (2008)

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome
por: Shakoor, Muhammad Tariq, et al.
Publicado: (2014)

Abciximab: Abciximab-induced alveolar haemorrhage: case report
Publicado: (2021)

The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008)

Spontaneous Bleeding from Internal Pudendal Artery associated with Abciximab after Primary Percutaneous Coronary Intervention: Successful Treatment with Percutaneous Gel-Foam Embolization
por: Lee, Seung-Eun, et al.
Publicado: (2016)

Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
por: Park, Soonyoung, et al.
Publicado: (2013)

Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab: design and rationale of the High Intensity Transient Signals ReoPro (HITS-RP) study
por: Kretzschmar, Daniel, et al.
Publicado: (2012)

Comparison between Intracoronary Abciximab and Intravenous Eptifibatide Administration during Primary Percutaneous Coronary Intervention of Acute ST-Segment Elevation Myocardial Infarction
por: Namazi, Mohammad Hasan, et al.
Publicado: (2013)

Efficacy of Femoral Vascular Closure Devices in Patients Treated with Anticoagulant, Abciximab or Thrombolytics during Percutaneous Endovascular Procedures
por: Kim, Ha Young, et al.
Publicado: (2006)

Early administration of abciximab reduces mortality in female patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (from the EUROTRANSFER Registry)
por: Dziewierz, Artur, et al.
Publicado: (2012)

A case of successful primary coronary intervention for the total occlusion of left main stem with the aid of abciximab.
por: Jeong, M. H., et al.
Publicado: (2001)

Effect of Intravenous Abciximab on Coronary Flow Improvement After Re-vascularization in Primary Coronary Intervention and Short Term Impact
por: Rgeeb, Ahmed N., et al.
Publicado: (2020)

Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy
por: Parodi, Guido, et al.
Publicado: (2010)

Alveolar Hemorrhage during Abciximab Infusion
por: Koza, Yavuzer, et al.
Publicado: (2021)

Effects of intracoronary antithrombotics on ventricular function: A comparison of tenecteplase versus abciximab during primary percutaneous intervention in myocardial infarction
por: Morales-Ponce, Francisco J., et al.
Publicado: (2021)

Intracoronary versus intravenous abciximab in ST-segment elevation myocardial infarction: rationale and design of the CICERO trial in patients undergoing primary percutaneous coronary intervention with thrombus aspiration
por: Gu, Youlan L, et al.
Publicado: (2009)

Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials
por: Bai, Nan, et al.
Publicado: (2022)

Anti-inflammatory Effect of Abciximab-Coated Stent in a Porcine Coronary Restenosis Model
por: Hong, Young Joon, et al.
Publicado: (2007)

Long-Term Clinical Benefits of a Platelet Glycoprotein IIb/IIIa Receptor Blocker, Abciximab (ReoPro(®)), in High-Risk Diabetic Patients undergoing Percutaneous Coronary Intervention
por: Sim, Doo Sun, et al.
Publicado: (2003)

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio
por: Voisard, Rainer, et al.
Publicado: (2006)

Intracoronary versus Intravenous Administration of Abciximab in Patients with Acute Coronary Syndrome: A Meta-Analysis
por: Wang, Jie-Ning, et al.
Publicado: (2013)

The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
por: Luo, Liman, et al.
Publicado: (2019)

Bilateral subconjunctival hemorrhage secondary to abciximab use: case report
por: Kul, Selim, et al.
Publicado: (2017)

Eptifibatide is associated with significant cost savings and similar clinical outcomes to abciximab when used during primary percutaneous coronary intervention for ST-elevation myocardial infarction: An observational cohort study of 3863 patients
por: Rathod, KS, et al.
Publicado: (2017)

Safety and efficacy of the Expressman Extension System for complex coronary lesions during percutaneous coronary intervention
por: Ma, Yanzhuo, et al.
Publicado: (2023)

Impact of the adjunctive use criteria for intravascular ultrasound-guided percutaneous coronary intervention and clinical outcomes
por: Suwannasom, Pannipa, et al.
Publicado: (2023)

Efficacy of Combination Treatment with Intracoronary Abciximab and Aspiration Thrombectomy on Myocardial Perfusion in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Coronary Stenting
por: Ahn, Sung Gyun, et al.
Publicado: (2014)

Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)

Percutaneous Coronary Interventions in Women
por: Joodi, Golsa, et al.
Publicado: (2023)

The Efficacy and Safety of Compound Danshen Dripping Pill Combined with Percutaneous Coronary Intervention for Coronary Heart Disease
por: Li, Cailan, et al.
Publicado: (2020)

Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
por: Li, Jianan, et al.
Publicado: (2021)

Effect of a Dual Drug-Coated Stent With Abciximab and Alpha-Lipoic Acid in a Porcine Coronary Restenosis Model
por: Lim, Kyung Seob, et al.
Publicado: (2011)

Safety and efficacy of dual antiplatelet therapy after percutaneous coronary interventions in patients with end-stage liver disease
por: Ostojic, Zvonimir, et al.
Publicado: (2021)

Efficacy and Safety of Shexiang Baoxin Pill for Coronary Heart Disease after Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis
por: Wei, Jingjing, et al.
Publicado: (2021)

Safety and efficacy of immediate heparin reversal with protamine after complex percutaneous coronary intervention
por: Choi, Jin Hee, et al.
Publicado: (2022)

Utility of adjunctive modalities in Coronary chronic total occlusion intervention
por: Bhatt, Hemal, et al.
Publicado: (2017)

Adjunctive Approaches to Aphasia Rehabilitation: A Review on Efficacy and Safety
por: Picano, Chiara, et al.
Publicado: (2021)

The safety of Ramadan Fasting following Percutaneous Coronary Intervention
por: Amin, Osama A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2vd6rgti2bb7f6v64dof5lv942